With the ELEVECTA™ Technology, CEVEC offers a unique solution for large-scale production of AAV vectors using helper virus-free producer cell lines with all necessary components stably integrated into the cell.
The CAP™ Technology comprises a portfolio of proprietary cell lines and platform technologies based on the CAP™ cells, a superior production cell line for complex biopharmaceuticals, including viral vectors, exosomes and complex proteins.
CEVEC’s CAP™ Ad Platform is based on the CAP™ cell line and is the ideal production platform for RCA-free Adenoviral vectors for gene therapy and vector vaccine applications.
With the CAP™ Go Platform CEVEC provides a solution to the increasing need for production of complex and highly glycosylated recombinant proteins, including laminins, coagulation factors and plasma proteins.